AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04972175 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 50-Hour Intervention - BC LisPram
Description: Subcutaneous-delivery of BC LisPram using pump therapy.
Study NCT04276701 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: blood sample
Description: 35 ml whole blood for Peripheral blood mononuclear cell (PBMC), serum and plasma
Study NCT04276701 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ultrasonography assessment
Description: assessment of atherosclerotic plaques and measurement of carotid intima-media thickness (cIMT)
Study NCT04276701 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: questionnaires
Description: Food and exercise questionnaires validated by the American heart Association
Study NCT05954104 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Calcipotriol
Description: To evaluate the efficacy of Calcipotriol on Alopecia Areata.
Study NCT05111964 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High Intensity Focused Ultrasound Ablation
Description: The focused ultrasound exposure will be performed using the Haifu® Model-JC200 Focused Ultrasound Tumour Therapeutic System at the Churchill Hospital site, CE-approved for tumour therapy (or subsequent CE-approved device upgrades by Haifu®). The participant will be positioned over the therapeutic device and water bath used to transmit the focused ultrasound to the target tumour. No anaesthesia or any combination of local anaesthesia, nerve block, epidural, conscious sedation or general anaesthetic may be used, depending on anatomical location, size of tumour, preference of HIFU team, patient and anaesthetist and other patient factors.~In therapy mode, the tumour volume is treated with focused ultrasound to ablate the tumour tissues to high temperatures (in excess of 60ºC) using focused ultrasound targeted from outside the body.~Patients are typically discharged with 24 hours.
Study NCT05111964 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Tumour Biopsy and Venous Blood Tests
Description: Where appropriate, participants are also encouraged to undergo a pre-HIFU (and in the case of unresectable STS, post-HIFU) ultrasound biopsy of the target tumour and additional blood tests to inform the immunological aspects of the study. Having the biopsy does not mandate enrolment on the trial, and patients will be free to leave the trial at any stage. The pre-HIFU (and post-HIFU) biopsies are altruistically encouraged but not absolutely essential to enrolment on the trial.~Biopsies will be performed under ultrasound guidance by an experienced radiologist using local anaesthetic.
Study NCT05554003 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide capsule
Description: Metronomic temozolomide 60 mg/die continuously
Study NCT05135312 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Etanercept
Description: TNF-alpha inhibitors improve nail psoriasis.
Study NCT05755113 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tigilanol Tiglate
Description: Tigilanol tiglate is a novel, short-chain diterpene ester in clinical development for intratumoural treatment of a wide range of solid tumours.
Study NCT04515719 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Belimumab
Description: Belimumab 2mg/kg intravenously
Study NCT04515719 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo intravenously
Study NCT05173350 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: RETAIN KY
Description: The experimental group receives a combination of medical provider services, stay-at-work (SAW)/return-to-work (RTW) coordination services, and other SAW/RTW services. Services offered by the project include individualized intensive vocational services from RETAIN RTW Coordinators, with an emphasis on assistive technology, universal design, and peer support. The project provides training on SAW/RTW best practices and RETAIN, as well as financial incentives to health care professionals. The treatment group is eligible to receive the full set of RETAIN intervention activities.
Study NCT05173350 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Active Comparator
Description: Those in the active comparator arm continue to receive medical services. A RTW coordinator creates a RTW plan with the enrollee and refers them to existing resources. The RTW coordinator works with enrollees for 2.5 hours total.
Study NCT05135312 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: OCT
Description: Optical Coherence Tomography is a noninvasive imaging device that can be used to monitor nail disease severity.
Study NCT05869084 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: pulmonary function tests
Description: pulmonary function tests
Study NCT05672004 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PUMP-fit strategy (implementation toolbox)
Description: Healthcare professionals will receive the ProMuscle training from one of the researchers during a one-hour online meeting (during the control period).~Healthcare professionals will be informed about the platform and toolbox. Healthcare professionals receive a personal log-in for the online platform. Healthcare professionals receive a questionnaire about their readiness for implementation. The results of this questionnaire are directly visible on the platform Within the separate environment of the online platform, healthcare professionals can access their implementation toolbox. The toolbox is tailored to their personal context based on the results of the 'Readinesstool'.
Study NCT05672004 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Implementation as usual
Description: First, healthcare professionals will receive the ProMuscle training from one of the researchers during a one-hour online meeting.~At the end of the training healthcare professionals are informed about the mandatory conditions to implement ProMuscle (champion, material, approval of management).~Healthcare professionals receive a questionnaire about their readiness for implementation. The results of this questionnaire are directly visible. Results contain a graph of possible barriers for implementation in their practice.~Hereafter they will be instructed to start with implementation as usual.
Study NCT05312216 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab plus Lenvatinib
Description: Durvalumab: 1500mg, iv.drip, Q4w Lenvatinib: 8mg, QD (body weight \< 60kg) or 12mg, QD (body weight ≥ 60kg)~Number of cycle: until subjects withdrawing the informed consent OR progressive disease OR developing unacceptable toxicity events
Study NCT04640129 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEG-Interferon Alfa, Tenofovir Disoproxil Fumarate
Description: Combination therapy group was treated with PEG-interferon Alfa in addition to TDF monotherapy
Study NCT04640129 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tenofovir Disoproxil Fumarate
Description: TDF monotherapy
Study NCT05444296 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Superficial Dry Needling
Description: 1/2 needles will placed into defined innervation fields of the trigeminal nerve and rotated. Total time will be 5-7 minutes.
Study NCT05423717 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daridorexant 10 mg
Description: Daridorexant will be taken orally, once daily in the evening during the treatment period.
Study NCT05423717 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daridorexant 25 mg
Description: Daridorexant will be taken orally, once daily in the evening during the treatment period.
Study NCT05423717 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daridorexant 50 mg
Description: Daridorexant will be taken orally, once daily in the evening during the treatment period.
Study NCT05423717 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be taken orally, once daily in the evening during the treatment period.
Study NCT06191159 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Scalpel and standard electrocautery or PEAK PlasmaBlade
Description: Scalpel followed by completion of surgery with standard electrocautery or PEAK PlasmaBlade.
Study NCT06191159 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PEAK PlasmaBlade
Description: PEAK PlasmaBlade for entire surgery.
Study NCT06191159 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Standard Electrocautery
Description: Standard Electrocautery for entire surgery.
Study NCT05444296 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Non-thrust Mobilizations only
Description: Non-thrust mobilizations to be applied to the most symptomatic level of the upper cervical spine as determined by a treating physical therapist. The mobilization technique will be applied for 3 bouts of 30 seconds.
Study NCT05444296 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Non-thrust Mobilizations only
Description: Non-thrust mobilizations to be applied to the most symptomatic level of the upper cervical spine as determined by a treating physical therapist. The mobilization technique will be applied for 3 bouts of 30 seconds.
Study NCT06626542 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: resistance and aerobic training exercises
Description: resistance and aerobic training exercises
Study NCT06626542 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: resistance and aerobic training exercises
Description: resistance and aerobic training exercises
Study NCT06430632 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Robotic Gait Training
Description: Participants will complete standing and walking activities while wearing a robotic exoskeleton. Participants will also be asked to complete questionnaires about their walking and function.
Study NCT06430632 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care Gait Training
Description: Participants will complete standing and walking activities such as body weight-supported treadmill training and conventional overground walking. Participants will also be asked to complete questionnaires about their walking and function.
Study NCT04899466 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ActiGraft
Description: Whole blood clot (WBC) gel
Study NCT05236465 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: A 3-day course
Description: The course is built on the LP manual (Parker, 2013) and includes stress theory, Positive Psychology and knowledge about regulating thoughts, feelings and behavior, and through that positively influencing physiology.
Study NCT05236465 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Waiting list
Description: Treatment as usual (TAU) in the first 10 weeks. After 10 weeks: Behavioural: A 3-day course. The course is built on the LP manual (Parker, 2013) and includes stress theory, Positive Psychology and knowledge about regulating thoughts, feelings and behavior, and through that positively influencing physiology.
Study NCT06581666 — intervention group
Intervention type: OTHER
Intervention: No special intervention, all participants will be asked to complete same set of questionnaire.
Description: No special intervention, all participants will be asked to complete same set of questionnaire.
Study NCT06265610 — intervention group
Intervention type: PROCEDURE
Intervention: TIVA/TCI
Description: : The aim of this study was to evaluate the effects of total intravenous anesthesia with target-controlled infusion (TCI/TIVA) on intraoperative hemodynamic parameters and postoperative awakening criteria in pediatric endovascular intervention patients
Study NCT05731687 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Hybrid DEB approach with drug-eluting balloon
Description: If a patient is randomized to the hybrid DEB approach, lesion preparation of the SB with non-compliant balloon (NC) is mandatory before DEB application. The application of DEB can be performed if acceptable result of the lesion preparation is obtained (at least TIMI III flow and no flow limiting dissection). The drug- eluting balloon used in this study is the CE- marked Magic Touch Sirolimus Coated Balloon Catheter (Concept Medical, Gujarat, India). The size of the DEB is measured on a ratio 1:1 on reference diameter of the SB. The DEB balloon is inflated for 60 seconds, or two times more than 30 seconds if long duration inflations are not possible. Finally low pressure kissing inflation with the same DEB in place, and Proximal Optimization Therapy (POT) are performed. In case of SB occlusion, or flow limiting dissections in non-Left Main (LM) bifurcations and \< TIMI 3 flow or 70-99% residual stenosis in LM bifurcations, cross- over to two-stent technique is performed.
Study NCT05731687 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Two-stent strategy
Description: When randomized to the conventional two-stent strategy, TAP/T or Culotte stenting is performed. First lesion preparation of the SB is mandatory. The drug-eluting stent (Supraflex stent) can be placed in the SB if acceptable result of the lesion preparation is obtained and is measured on a 1:1 ratio on reference diameter of the SB. Finally, kissing inflation and POT are mandatory.
Study NCT05826119 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: magnesium sulfate group
Description: Anesthesia induction was provided with propofol (2mg/kg), fentanyl (2mcg/kg). Intubation was performed after administration of 0.6 mg/kg rocuronium with an appropriate endotracheal tube. Anesthesia was maintained using AIR/O2 (50%/50%), 1 minimum alveolar concentration (MAC) sevoflurane, 0.1-0.25 mcg/kg/min remifentanil infusion. The target BIS value was kept between 40 and 50. Systolic blood pressure (SBP) \<90mmHg or \<20% of baseline was considered hypotension; remifentanil infusion was reduced. If no response was obtained, 5-10 mg of IV ephedrine was administered. HR \< 45 beats/min was evaluated as bradycardia; IV atropine 0.5 mg was planned The magnesium group received a bolus of 20 mg/kg of magnesium sulfate in 100 mL of saline for 15 minutes prior to induction, followed by a continuous infusion of 20 mg/kg/hr until skin closure.
Study NCT05826119 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Anesthesia induction was provided with propofol (2mg/kg), fentanyl (2mcg/kg). Intubation was performed after administration of 0.6 mg/kg rocuronium with an appropriate endotracheal tube. Anesthesia was maintained using AIR/O2 (50%/50%), 1 minimum alveolar concentration (MAC) sevoflurane, 0.1-0.25 mcg/kg/min remifentanil infusion. The target BIS value was kept between 40 and 50. Systolic blood pressure (SBP) \<90mmHg or \<20% of baseline was considered hypotension; remifentanil infusion was reduced. If no response was obtained, 5-10 mg of IV ephedrine was administered. HR \< 45 beats/min was evaluated as bradycardia; IV atropine 0.5 mg was planned The same volume of isotonic saline for the control group was administered as indicated in the magnesium group.
Study NCT06627127 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Target stimulation (HGN, AC, GG, Strap muscles)
Description: Stimulation of the HGN or GG along with AC or strap muscles.
Study NCT05429463 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sintilimab
Description: 200 mg by IV infusion every 3 weeks (Q3W), given on cycle day 1.
Study NCT05429463 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: AUC 5-6 mg/mL/min by IV infusion Q3W, given on cycle day 1.
Study NCT05429463 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albumin-Bound Paclitaxel
Description: 260 mg/m\^2 by IV infusion Q3W, given on cycle day 1.
Study NCT06729632 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cold pack-delivered mild therapeutic hypothermia
Description: Mild therapeutic hypothermia (cooling), delivered non-invasively to the structures of the inner ear (cochlea) for 30 minutes, using headband-style proprietary device, ReBoundRx.
Study NCT06729632 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cold pack-delivered mild therapeutic hypothermia
Description: Mild therapeutic hypothermia (cooling), delivered non-invasively to the structures of the inner ear (cochlea) for 30 minutes, using headband-style proprietary device, ReBoundRx.
Study NCT06742450 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Constant current (CC) subthalamic nucleus deep brain stimulation
Description: For subjects who have decided to undergo STN-DBS surgery and meet the inclusion criteria, the constant current (CC) mode is selected as the original electronic modality one week after surgery. Regardless of any changes in programming parameters over the following year, the constant current (CC) mode will be maintained.
Study NCT06742450 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Constant voltage (CV) subthalamic nucleus deep brain stimulation
Description: For subjects who have decided to undergo STN-DBS surgery and meet the inclusion criteria, the constant voltage (CV) mode is selected as the original electronic modality one week after surgery. Regardless of any changes in programming parameters over the following year, the constant voltage (CV) mode will be maintained.
Study NCT06741514 — intervention group
Intervention type: DEVICE
Intervention: Precice IMLL
Description: Parents or legal guardians of children that previously received the Precice IMLL will complete a survey. No additional or new interventions will be administered.
Study NCT06741475 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Caregiver-Assist Strategy Training
Description: CaST is a home-based rehabilitation that guides both stroke survivors and their caregivers to implement strategy training for addressing real-life limitations after stroke. During the intervention, the caregiver not only supervises the participant but also co-participates in the practice by instructing on when and how to be an assistant and facilitator when the stroke survivor executes their practice plan.
Study NCT06741475 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Education
Description: Stroke-related information and knowledge that includes stroke subtypes and their etiology, risk factors of primary and secondary stroke, healthy lifestyles, common sequela, and adaptive skills for impaired functions are provided.
Study NCT06742463 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: BCL-2 inhibitor
Study NCT06742463 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: homoharringtonine
Description: alkaloid
Study NCT06742463 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine (Ara-C)
Description: Metabolic antagonist.
Study NCT06742463 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G-CSF
Description: Granulocyte colony-stimulating factor
Study NCT06743113 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hemanext ONE System
Description: Hypoxic red blood cells
Study NCT06743113 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional RBCs
Description: Conventional red blood cells
Study NCT06741917 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levofloxacin
Description: single dose of oral Levofloxacin (500mg/tab) before retrograde intrarenal surgery
Study NCT06741917 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cefmetazole (drug)
Description: single dose of intravenous Cefmetazole (1000 mg)before retrograde intrarenal surgery
Study NCT06741553 — intervention group
Intervention type: DRUG
Intervention: Lecanemab 10 mg/kg
Description: Lecanemab was administered 10mg/kg every two weeks.
Study NCT06743152 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Synchronous exercise program
Description: The synchronous exercise group will be conducted online with synchronous supervision under the supervision of a physiotherapist. The exercise program will be performed for 8 weeks, 2 days a week. In the exercise program, 3 sets, 8 repetitions in 1 set will be progressed to 10-12-15-20-25 repetitions according to tolerance. There will be a 1-2 minute rest between sets.
Study NCT06743152 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Asynchronous exercise group
Description: The Asynchronous Exercise Group will be conducted with a video-based structured exercise program. For the asynchronous video-based group, a closed channel will be created on Youtube that only patients can access, and the exercises will be uploaded to the system asynchronously. In the asynchronous exercise group, how each exercise is performed will be shown in detail by the physiotherapist in the video content.
Study NCT06742658 — intervention group
Intervention type: OTHER
Intervention: Rapid Move
Description: A short-stay PACU where patients recover from anaesthesia, are continuously monitored, and prepared for discharge within an hour after surgery.
Study NCT06743178 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Photo of a person injecting drugs
Description: Exposed to a photo of a person injecting drugs
Study NCT06743178 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Photo of EMS responding to an overdose (White)
Description: Exposed to a photo of EMS responding to an overdose (White)
Study NCT06743178 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Photo of EMS responding to an overdose (Black)
Description: Exposed to a photo of EMS responding to an overdose (Black)
Study NCT06743178 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Photo of a person receiving treatment (Jail)
Description: Exposed to a photo of a person receiving treatment (Jail)
Study NCT06743178 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Photo of a person receiving treatment (Community)
Description: Exposed to a photo of a person receiving treatment (Community)
Study NCT06743178 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Photo of a person in recovery (White)
Description: Exposed to a photo of a person in recovery (White)